Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
1.
Article in English | MEDLINE | ID: mdl-38887812

ABSTRACT

In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

3.
bioRxiv ; 2024 Apr 27.
Article in English | MEDLINE | ID: mdl-38712077

ABSTRACT

Physical particles can serve as critical abiotic factors that structure the ecology of microbial communities. For non-human vertebrate gut microbiomes, fecal particle size (FPS) has been known to be shaped by chewing efficiency and diet. However, little is known about what drives FPS in the human gut. Here, we analyzed FPS by laser diffraction across a total of 76 individuals and found FPS to be strongly individualized. Surprisingly, a behavioral intervention with 41 volunteers designed to increase chewing efficiency did not impact FPS. Dietary patterns could also not be associated with FPS. Instead, we found evidence that mammalian and human gut microbiomes shaped FPS. Fecal samples from germ-free and antibiotic-treated mice exhibited increased FPS relative to colonized mice. In humans, markers of longer transit time were correlated with smaller FPS. Gut microbiota diversity and composition were also associated with FPS. Finally, ex vivo culture experiments using human fecal microbiota from distinct donors showed that differences in microbiota community composition can drive variation in particle size. Together, our results support an ecological model in which the human gut microbiome plays a key role in reducing the size of food particles during digestion, and that the microbiomes of individuals vary in this capacity. These new insights also suggest FPS in humans to be governed by processes beyond those found in other mammals and emphasize the importance of gut microbiota in shaping their own abiotic environment.

5.
BMJ Case Rep ; 17(1)2024 Jan 03.
Article in English | MEDLINE | ID: mdl-38171636

ABSTRACT

Neuroendocrine tumours (NETs) are rare cancers which often carry significant morbidity and mortality, frequently related to burden of liver metastases. Hyperammonaemia and subsequent hepatic encephalopathy carries a poor prognosis and has been described in these patients. We discuss a case of a woman in her 50s with hyperammonaemic encephalopathy and a new diagnosis of pancreatic NET with hepatic metastases. She presented with a reduced conscious state a few days post commencing chemotherapy. This was considered to have a multifactorial pathophysiology: the primary driver being large volume hepatic metastases and contributed by portosystemic microshunting, sepsis, severe weight loss and malnutrition. We describe how each of these exacerbating factors was addressed and highlight the effective multimodal treatment approach consisting of sequential transarterial chemoembolisation followed by peptide receptor radio nucleotide therapy, resulting in the resolution of hyperammonaemic encephalopathy and radiological partial metabolic response.


Subject(s)
Brain Diseases , Chemoembolization, Therapeutic , Liver Neoplasms , Neoplasms, Second Primary , Neuroendocrine Tumors , Pancreatic Neoplasms , Female , Humans , Neuroendocrine Tumors/therapy , Neuroendocrine Tumors/secondary , Liver Neoplasms/therapy , Liver Neoplasms/secondary , Chemoembolization, Therapeutic/methods , Neoplasms, Second Primary/therapy , Pancreatic Neoplasms/complications , Pancreatic Neoplasms/therapy , Brain Diseases/therapy
6.
J Prim Care Community Health ; 14: 21501319231208517, 2023.
Article in English | MEDLINE | ID: mdl-37933555

ABSTRACT

BACKGROUND: The highest prescribing rates for antibiotics occur in primary care, therefore, ambulatory care pharmacist interventions could play a major role in preventing overuse and misuse of antibiotics. Delegated pharmacists in the SJC primary care setting guided 3 activities with a goal of positively impacting prescribing patterns: monthly webinars provided by Agency for Healthcare Research and Quality (AHRQ), quarterly reporting to physicians of antibiotic prescribing patterns, and development of a clinical decision-making support tool for antibiotic prescribing. METHODS: Retrospective, observational data was collected to evaluate antibiotic prescribing patterns in patients diagnosed with acute sinusitis both before initiatives were implemented (July 1, 2019 through June 30, 2020) and after the initiatives were implemented (April 1, 2022 through June 30, 2022). RESULTS: A total of 675 patients were diagnosed with acute bacterial sinusitis during the specified time frame. Of these, 138 patients were excluded. A total of 279 antibiotics were prescribed in the preintervention group out of 298 patient encounters (93.6%) and 225 antibiotics were prescribed in the post-intervention group out of 244 patient encounters (92.9%) (p = .26). Although the primary outcome was not statistically significant, a significant reduction in patients treated with fluoroquinolones was noted, with 59/298 (20%) of those being prescribed in the pre-intervention group and 20/244 (8%) in the post intervention group (P = .02). CONCLUSIONS: While pharmacist-led antimicrobial stewardship interventions in primary care did not result in a decrease in the overall prescription of antibiotics for acute sinusitis, our study did reveal a notable reduction in the use of fluoroquinolones. This finding highlights a promising avenue for expanding the role of ambulatory care pharmacists.


Subject(s)
Antimicrobial Stewardship , Sinusitis , Humans , Retrospective Studies , Sinusitis/drug therapy , Anti-Bacterial Agents/therapeutic use , Primary Health Care , Practice Patterns, Physicians'
7.
Opt Lett ; 48(17): 4717-4720, 2023 Sep 01.
Article in English | MEDLINE | ID: mdl-37656594

ABSTRACT

Future gravitational wave detectors (GWDs) require low noise, single frequency, continuous wave lasers with excellent beam quality and powers in excess of 500 W. Low noise laser amplifiers with high spatial purity have been demonstrated up to 300 W. For higher powers, coherent beam combination can overcome scaling limitations. In this Letter we introduce a new, to the best of our knowledge, combination scheme that uses a bow-tie resonator to combine three laser beams with simultaneous spatial filtering performance.

8.
Nat Microbiol ; 8(8): 1450-1467, 2023 08.
Article in English | MEDLINE | ID: mdl-37337046

ABSTRACT

Akkermansia muciniphila, a mucophilic member of the gut microbiota, protects its host against metabolic disorders. Because it is genetically intractable, the mechanisms underlying mucin metabolism, gut colonization and its impact on host physiology are not well understood. Here we developed and applied transposon mutagenesis to identify genes important for intestinal colonization and for the use of mucin. An analysis of transposon mutants indicated that de novo biosynthesis of amino acids was required for A. muciniphila growth on mucin medium and that many glycoside hydrolases are redundant. We observed that mucin degradation products accumulate in internal compartments within bacteria in a process that requires genes encoding pili and a periplasmic protein complex, which we term mucin utilization locus (MUL) genes. We determined that MUL genes were required for intestinal colonization in mice but only when competing with other microbes. In germ-free mice, MUL genes were required for A. muciniphila to repress genes important for cholesterol biosynthesis in the colon. Our genetic system for A. muciniphila provides an important tool with which to uncover molecular links between the metabolism of mucins, regulation of lipid homeostasis and potential probiotic activities.


Subject(s)
Intestines , Mucins , Verrucomicrobia , Animals , Mice , Mucins/metabolism , Sterols/biosynthesis , Verrucomicrobia/genetics , Verrucomicrobia/growth & development , Verrucomicrobia/metabolism , Intestines/microbiology , Specific Pathogen-Free Organisms , DNA Transposable Elements/genetics , Mutagenesis , Host Microbial Interactions/genetics , Intracellular Space/metabolism , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Transcription, Genetic
10.
Australas J Dermatol ; 64(2): 221-228, 2023 May.
Article in English | MEDLINE | ID: mdl-36961092

ABSTRACT

BACKGROUND: Intravenous immunoglobulins (IVIG) have been increasingly used for various inflammatory dermatoses with success. Small case series and case reports suggest a role for IVIG in the management of refractory pyoderma gangrenosum (PG). OBJECTIVE: The objective was to study the characteristics of PG patients treated with IVIG and the efficacy and safety of IVIG for patients with refractory PG. METHODS: An analysis was performed of all patients with PG treated with IVIG from 2012 to 2022 at an Australian tertiary hospital seeing a high volume of PG patients. RESULTS: We identified 12 patients, 9 females and 3 males, with median age of 61 years (29-77) at IVIG commencement. All patients were taking systemic corticosteroid therapy prior to IVIG treatment, and all had been treated with a steroid-sparing agent-including ten patients who had been treated with a biologic agent. IVIG was used with corticosteroids in one patient, concurrently with a steroid-sparing agent in nine patients and with a biologic agent in eight patients. Eleven patients demonstrated treatment response to IVIG-six with excellent response and five with good response. Three patients had complete healing of their most active ulcer. One patient did not respond to IVIG. Nine patients were able to wean their prednisolone dose and one patient was able to cease prednisolone. Four adverse events were recorded, and only one patient had to cease treatment due to aseptic meningitis and headaches. CONCLUSION: Our experience suggests that IVIG may be an efficacious treatment for patients with refractory PG due to its pleiotropic and immunomodulatory effects, particularly for patients with malignancy or other systemic conditions where high-dose immunosuppressive agents are contraindicated.


Subject(s)
Immunoglobulins, Intravenous , Pyoderma Gangrenosum , Male , Female , Humans , Adult , Middle Aged , Aged , Immunoglobulins, Intravenous/therapeutic use , Pyoderma Gangrenosum/drug therapy , Pyoderma Gangrenosum/etiology , Australia , Prednisolone/therapeutic use , Biological Factors/therapeutic use
12.
BMJ Case Rep ; 15(8)2022 Aug 10.
Article in English | MEDLINE | ID: mdl-35948362

ABSTRACT

A woman with metastatic melanoma was treated with immunotherapy induction with ipilimumab and nivolumab and radiotherapy to liver metastases. The patient deteriorated shortly thereafter, becoming febrile and hypotensive and requiring admission to the intensie care unit (ICU) for inotrope support. Failure to respond to antibiotics and a negative septic screen prompted further investigation, which ultimately led to a diagnosis of haemophagocytic lymphohistiocytosis (HLH). The patient improved on high dose steroids and was discharged home. Months later, in the context of progressive melanoma, the patient was re-challenged with nivolumab monotherapy and subsequently experienced recurrence of HLH, confirming the aetiology as being immunotherapy related. This case serves as a reminder to consider HLH where there are fevers of unknown origin in an unwell patient receiving immune checkpoint inhibitor therapy and also highlights immunotherapy as a potential cause for HLH, which has rarely been reported in the literature to date.


Subject(s)
Antineoplastic Agents, Immunological , Lymphohistiocytosis, Hemophagocytic , Melanoma , Neoplasms, Second Primary , Antineoplastic Agents, Immunological/adverse effects , Female , Humans , Immune Checkpoint Inhibitors , Immunologic Factors/therapeutic use , Immunotherapy/adverse effects , Ipilimumab/adverse effects , Lymphohistiocytosis, Hemophagocytic/chemically induced , Lymphohistiocytosis, Hemophagocytic/drug therapy , Melanoma/pathology , Neoplasms, Second Primary/drug therapy , Nivolumab/adverse effects
13.
ISME J ; 16(11): 2479-2490, 2022 Nov.
Article in English | MEDLINE | ID: mdl-35871250

ABSTRACT

Many ecosystems have been shown to retain a memory of past conditions, which in turn affects how they respond to future stimuli. In microbial ecosystems, community disturbance has been associated with lasting impacts on microbiome structure. However, whether microbial communities alter their response to repeated stimulus remains incompletely understood. Using the human gut microbiome as a model, we show that bacterial communities retain an "ecological memory" of past carbohydrate exposures. Memory of the prebiotic inulin was encoded within a day of supplementation among a cohort of human study participants. Using in vitro gut microbial models, we demonstrated that the strength of ecological memory scales with nutrient dose and persists for days. We found evidence that memory is seeded by transcriptional changes among primary degraders of inulin within hours of nutrient exposure, and that subsequent changes in the activity and abundance of these taxa are sufficient to enhance overall community nutrient metabolism. We also observed that ecological memory of one carbohydrate species impacts microbiome response to other carbohydrates, and that an individual's habitual exposure to dietary fiber was associated with their gut microbiome's efficiency at digesting inulin. Together, these findings suggest that the human gut microbiome's metabolic potential reflects dietary exposures over preceding days and changes within hours of exposure to a novel nutrient. The dynamics of this ecological memory also highlight the potential for intra-individual microbiome variation to affect the design and interpretation of interventions involving the gut microbiome.


Subject(s)
Gastrointestinal Microbiome , Microbiota , Dietary Fiber , Gastrointestinal Microbiome/physiology , Humans , Inulin , Nutrients
14.
Microbiome ; 10(1): 114, 2022 07 29.
Article in English | MEDLINE | ID: mdl-35902900

ABSTRACT

BACKGROUND: Short-chain fatty acids (SCFAs) derived from gut bacteria are associated with protective roles in diseases ranging from obesity to colorectal cancers. Intake of microbially accessible dietary fibers (prebiotics) lead to varying effects on SCFA production in human studies, and gut microbial responses to nutritional interventions vary by individual. It is therefore possible that prebiotic therapies will require customizing to individuals. RESULTS: Here, we explored prebiotic personalization by conducting a three-way crossover study of three prebiotic treatments in healthy adults. We found that within individuals, metabolic responses were correlated across the three prebiotics. Individual identity, rather than prebiotic choice, was also the major determinant of SCFA response. Across individuals, prebiotic response was inversely related to basal fecal SCFA concentration, which, in turn, was associated with habitual fiber intake. Experimental measures of gut microbial SCFA production for each participant also negatively correlated with fiber consumption, supporting a model in which individuals' gut microbiota are limited in their overall capacity to produce fecal SCFAs from fiber. CONCLUSIONS: Our findings support developing personalized prebiotic regimens that focus on selecting individuals who stand to benefit, and that such individuals are likely to be deficient in fiber intake. Video Abstract.


Subject(s)
Gastrointestinal Microbiome , Prebiotics , Adult , Cross-Over Studies , Dietary Fiber/administration & dosage , Fatty Acids, Volatile/analysis , Feces/chemistry , Gastrointestinal Microbiome/physiology , Humans
15.
JCI Insight ; 7(8)2022 04 22.
Article in English | MEDLINE | ID: mdl-35451370

ABSTRACT

Systemic sclerosis (SSc) is a fibrotic autoimmune disease characterized by pathogenic activation of fibroblasts enhanced by local oxidative stress. The tyrosine phosphatase PTP4A1 was identified as a critical promoter of TGF-ß signaling in SSc. Oxidative stress is known to functionally inactivate tyrosine phosphatases. Here, we assessed whether oxidation of PTP4A1 modulates its profibrotic action and found that PTP4A1 forms a complex with the kinase SRC in scleroderma fibroblasts, but surprisingly, oxidative stress enhanced rather than reduced PTP4A1's association with SRC and its profibrotic action. Through structural assessment of the oxo-PTP4A1-SRC complex, we unraveled an unexpected mechanism whereby oxidation of a tyrosine phosphatase promotes its function through modification of its protein complex. Considering the importance of oxidative stress in the pathogenesis of SSc and fibrosis, our findings suggest routes for leveraging PTP4A1 oxidation as a potential strategy for developing antifibrotic agents.


Subject(s)
Scleroderma, Systemic , Fibroblasts/metabolism , Fibrosis , Humans , Oxidative Stress , Scleroderma, Systemic/pathology , Tyrosine/metabolism
16.
Microb Cell Fact ; 20(1): 211, 2021 Nov 16.
Article in English | MEDLINE | ID: mdl-34784924

ABSTRACT

Many applications of microbial synthetic biology, such as metabolic engineering and biocomputing, are increasing in design complexity. Implementing complex tasks in single populations can be a challenge because large genetic circuits can be burdensome and difficult to optimize. To overcome these limitations, microbial consortia can be engineered to distribute complex tasks among multiple populations. Recent studies have made substantial progress in programming microbial consortia for both basic understanding and potential applications. Microbial consortia have been designed through diverse strategies, including programming mutualistic interactions, using programmed population control to prevent overgrowth of individual populations, and spatial segregation to reduce competition. Here, we highlight the role of microbial consortia in the advances of metabolic engineering, biofilm production for engineered living materials, biocomputing, and biosensing. Additionally, we discuss the challenges for future research in microbial consortia.


Subject(s)
Biofilms , Biosensing Techniques , Metabolic Engineering/methods , Microbial Consortia , Industrial Microbiology , Synthetic Biology
17.
BMJ Case Rep ; 14(6)2021 Jun 16.
Article in English | MEDLINE | ID: mdl-34135074

ABSTRACT

Bacterial endocarditis remains a challenging condition to manage owing to its variety of different presentations. This report describes a 55-year-old woman with endocarditis who presented confused with shoulder and back pain. Initial diagnosis was made difficult by a negative echocardiogram but aided by striking peripheral stigmata. She was treated for infective endocarditis as she met all five Duke's minor criteria for infective endocarditis. Gallium scan was a useful investigation in identifying lumbar spine and acromioclavicular joint septic foci. This case highlights the challenges of diagnosing endocarditis. It also describes how gallium scans can be useful in identifying occult septic emboli in these patients.


Subject(s)
Endocarditis, Bacterial , Endocarditis , Echocardiography , Endocarditis/diagnostic imaging , Endocarditis/drug therapy , Endocarditis, Bacterial/diagnostic imaging , Endocarditis, Bacterial/drug therapy , Female , Humans , Intensive Care Units , Middle Aged
18.
mBio ; 12(3)2021 05 18.
Article in English | MEDLINE | ID: mdl-34006653

ABSTRACT

The mucophilic anaerobic bacterium Akkermansia muciniphila is a prominent member of the gastrointestinal (GI) microbiota and the only known species of the Verrucomicrobia phylum in the mammalian gut. A high prevalence of A. muciniphila in adult humans is associated with leanness and a lower risk for the development of obesity and diabetes. Four distinct A. muciniphila phylogenetic groups have been described, but little is known about their relative abundance in humans or how they impact human metabolic health. In this study, we isolated and characterized 71 new A. muciniphila strains from a cohort of children and adolescents undergoing treatment for obesity. Based on genomic and phenotypic analysis of these strains, we found several phylogroup-specific phenotypes that may impact the colonization of the GI tract or modulate host functions, such as oxygen tolerance, adherence to epithelial cells, iron and sulfur metabolism, and bacterial aggregation. In antibiotic-treated mice, phylogroups AmIV and AmII outcompeted AmI strains. In children and adolescents, AmI strains were most prominent, but we observed high variance in A. muciniphila abundance and single phylogroup dominance, with phylogroup switching occurring in a small subset of patients. Overall, these results highlight that the ecological principles determining which A. muciniphila phylogroup predominates in humans are complex and that A. muciniphila strain genetic and phenotypic diversity may represent an important variable that should be taken into account when making inferences as to this microbe's impact on its host's health.IMPORTANCE The abundance of Akkermansia muciniphila in the gastrointestinal (GI) tract is linked to multiple positive health outcomes. There are four known A. muciniphila phylogroups, yet the prevalence of these phylogroups and how they vary in their ability to influence human health is largely unknown. In this study, we performed a genomic and phenotypic analysis of 71 A. muciniphila strains and identified phylogroup-specific traits such as oxygen tolerance, adherence, and sulfur acquisition that likely influence colonization of the GI tract and differentially impact metabolic and immunological health. In humans, we observed that single Akkermansia phylogroups predominate at a given time but that the phylotype can switch in an individual. This collection of strains provides the foundation for the functional characterization of A. muciniphila phylogroup-specific effects on the multitude of host outcomes associated with Akkermansia colonization, including protection from obesity, diabetes, colitis, and neurological diseases, as well as enhanced responses to cancer immunotherapies.


Subject(s)
Genetic Variation , Genotype , Phenotype , Akkermansia/classification , Akkermansia/genetics , Akkermansia/isolation & purification , Animals , Cohort Studies , Female , Gastrointestinal Microbiome , HT29 Cells , Humans , Mice , Mice, Inbred C57BL , Phylogeny , RNA, Ribosomal, 16S/genetics , Sequence Analysis, DNA
19.
J Med Chem ; 64(9): 5645-5653, 2021 05 13.
Article in English | MEDLINE | ID: mdl-33914534

ABSTRACT

Obesity-associated insulin resistance plays a central role in the pathogenesis of type 2 diabetes. A promising approach to decrease insulin resistance in obesity is to inhibit the protein tyrosine phosphatases that negatively regulate insulin receptor signaling. The low-molecular-weight protein tyrosine phosphatase (LMPTP) acts as a critical promoter of insulin resistance in obesity by inhibiting phosphorylation of the liver insulin receptor activation motif. Here, we report development of a novel purine-based chemical series of LMPTP inhibitors. These compounds inhibit LMPTP with an uncompetitive mechanism and are highly selective for LMPTP over other protein tyrosine phosphatases. We also report the generation of a highly orally bioavailable purine-based analogue that reverses obesity-induced diabetes in mice.


Subject(s)
Enzyme Inhibitors/chemistry , Protein Tyrosine Phosphatases/antagonists & inhibitors , Purines/chemistry , Administration, Oral , Animals , Binding Sites , Crystallography, X-Ray , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/etiology , Disease Models, Animal , Drug Evaluation, Preclinical , Enzyme Inhibitors/metabolism , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/therapeutic use , Half-Life , Humans , Insulin Resistance , Kinetics , Molecular Dynamics Simulation , Obesity/complications , Obesity/pathology , Phosphorylation/drug effects , Protein Tyrosine Phosphatases/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Purines/metabolism , Purines/pharmacology , Purines/therapeutic use , Signal Transduction/drug effects , Structure-Activity Relationship
20.
J Cell Physiol ; 236(9): 6630-6642, 2021 09.
Article in English | MEDLINE | ID: mdl-33615467

ABSTRACT

Obesity is a major contributing factor to the pathogenesis of Type 2 diabetes. Multiple human genetics studies suggest that high activity of the low molecular weight protein tyrosine phosphatase (LMPTP) promotes metabolic syndrome in obesity. We reported that LMPTP is a critical promoter of insulin resistance in obesity by regulating liver insulin receptor signaling and that inhibition of LMPTP reverses obesity-associated diabetes in mice. Since LMPTP is expressed in adipose tissue but little is known about its function, here we examined the role of LMPTP in adipocyte biology. Using conditional knockout mice, we found that selective deletion of LMPTP in adipocytes impaired obesity-induced subcutaneous adipocyte hypertrophy. We assessed the role of LMPTP in adipogenesis in vitro, and found that LMPTP deletion or knockdown substantially impaired differentiation of primary preadipocytes and 3T3-L1 cells into adipocytes, respectively. Inhibition of LMPTP in 3T3-L1 preadipocytes also reduced adipogenesis and expression of proadipogenic transcription factors peroxisome proliferator activated receptor gamma (PPARγ) and CCAAT/enhancer-binding protein alpha. Inhibition of LMPTP increased basal phosphorylation of platelet-derived growth factor receptor alpha (PDGFRα) on activation motif residue Y849 in 3T3-L1, resulting in increased activation of the mitogen-associated protein kinases p38 and c-Jun N-terminal kinase and increased PPARγ phosphorylation on inhibitory residue S82. Analysis of the metabolome of differentiating 3T3-L1 cells suggested that LMPTP inhibition decreased cell glucose utilization while enhancing mitochondrial respiration and nucleotide synthesis. In summary, we report a novel role for LMPTP as a key driver of adipocyte differentiation via control of PDGFRα signaling.


Subject(s)
Adipocytes/metabolism , Adipocytes/pathology , Adipogenesis , Protein Tyrosine Phosphatases/metabolism , Proto-Oncogene Proteins/metabolism , Subcutaneous Fat/pathology , 3T3-L1 Cells , Adipogenesis/genetics , Animals , Cell Differentiation/genetics , Cell Respiration , Cell Size , Electron Transport , Gene Deletion , Gene Expression Regulation , Glucose/metabolism , Glycolysis , Hypertrophy , JNK Mitogen-Activated Protein Kinases/metabolism , Metabolome , Mice , Mice, Knockout , Mitochondria/metabolism , Models, Biological , PPAR gamma/metabolism , Phosphorylation , Phosphoserine/metabolism , Protein Tyrosine Phosphatases/antagonists & inhibitors , Proto-Oncogene Proteins/antagonists & inhibitors , Receptor, Platelet-Derived Growth Factor alpha/metabolism , Signal Transduction , p38 Mitogen-Activated Protein Kinases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...